We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01800045
Recruitment Status : Completed
First Posted : February 27, 2013
Last Update Posted : August 31, 2016
Information provided by (Responsible Party):

Brief Summary:

Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks per week).

The patients will be treated during 7 weeks with Pitolisant or placebo.

Condition or disease Intervention/treatment Phase
Narcolepsy With Cataplexy Excessive Daytime Sleepiness Drug: Pitolisant Drug: Placebo Phase 3

Detailed Description:

The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by verifying whether the results of Pitolisant are superior to those of placebo.

The safety will also be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 103 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.
Study Start Date : April 2013
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Pitolisant
Pitolisant at 5, 10, 20 or 40mg
Drug: Pitolisant
1 capsule in the morning before breakfast
Other Name: BF2.649

Placebo Comparator: Placebo
Capsules of placebo containing lactose
Drug: Placebo
1 capsule in the morning before breakfast
Other Name: Capsules of placebo containing lactose

Primary Outcome Measures :
  1. Measure of anticataplectic efficacy [ Time Frame: At week 7 ]
    Measure of anticataplectic efficacy assessed by the change in the average number of cataplexy attacks per week.

Secondary Outcome Measures :
  1. Excessive Daytime Sleepiness assessment [ Time Frame: At week 7 ]
    Excessive Daytime Sleepiness assessment by evaluation of ESS score, and other questionnaires.

  2. Safety assessment [ Time Frame: 11 weeks ]
    Safety assessment thanks to AE recording, vitals signs assessment, ECG...

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Narcoleptic with cataplexy : at least 3 weekly cataplexy attacks
  • ESS > or = 12
  • ICF signed and dated

Main Exclusion Criteria:

  • Other conditions that could generate EDS
  • Psychological and neurological disorders
  • Acute or chronic severe disease
  • Treatment by prohibited medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01800045

Layout table for location information
State Health Center
Budapest, Hungary, 1134
Sponsors and Collaborators
Layout table for investigator information
Study Director: Evelyne De Paillette, Dr Bioprojet
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bioprojet
ClinicalTrials.gov Identifier: NCT01800045    
Other Study ID Numbers: P11-05 / Pitolisant
2012-003076-39 ( EudraCT Number )
First Posted: February 27, 2013    Key Record Dates
Last Update Posted: August 31, 2016
Last Verified: July 2015
Keywords provided by Bioprojet:
Sleep disorder
Excessive daytime sleepiness
Additional relevant MeSH terms:
Layout table for MeSH terms
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders